Table 4 Late sequelae by treatment group
Late sequelae | Late sequelae independent of recurrence timepoint | Late sequelae before recurrencea | ||||
|---|---|---|---|---|---|---|
ASCT | MT | P-valuea | ASCT | MT | P-valuea | |
Intention to treat | % of 149 | % of 146 | % of 149 | % of 146 | ||
Auditory impairment | 25 | 20 | 0.330 | 20 | 13 | 0.118 |
Renal impairment | 8 | 10 | 0.550 | 6 | 7 | 0.816 |
Thyroid dysfunction | 9 | 8 | 0.440 | 8 | 8 | 1.000 |
Focal nodular hyperplasia of the liver | 6 | 1 | 0.019 | 6 | 1 | 0.019 |
Hepatopathy | 4 | 1 | 0.121 | 3 | 1 | 0.214 |
Peripheral neuropathy | <1 | <1 | 1.000 | 0 | <1 | 0.244 |
Growth retardation | 2 | 3 | 0.721 | 1 | 3 | 0.444 |
Cardiomyopathy | 0 | 2 | 0.120 | 0 | 2 | 0.120 |
Residual transverse myelopathy | 0 | <1 | 0.495 | 0 | <1 | 0.495 |
Persisting thrombocytopenia | <1 | <1 | 1.000 | <1 | <1 | 1.000 |
Visual impairment | 2 | 3 | 0.498 | 1 | 2 | 0.682 |
As treated | % of 110 | % of 102 | % of 110 | % of 102 | ||
Auditory impairment | 31 | 21 | 0.116 | 21 | 19 | 0.732 |
Renal impairment | 8 | 11 | 0.640 | 6 | 9 | 0.606 |
Thyroid dysfunction | 12 | 7 | 0.247 | 11 | 7 | 0.344 |
Focal nodular hyperplasia of the liver | 6 | 1 | 0.067 | 6 | 1 | 0.067 |
Hepatopathy | 3 | 1 | 0.623 | 3 | 1 | 0.623 |
Peripheral neuropathy | <1 | 0 | 1.000 | <1 | 0 | 1.000 |
Growth retardation | 2 | 1 | 1.000 | 2 | 1 | 1.000 |
Cardiomyopathy | 0 | 2 | 0.230 | 0 | 2 | 0.230 |
Residual transverse myelopathy | 0 | 1 | 0.481 | 0 | 1 | 0.481 |
Persisting thrombocytopenia | <1 | 0 | 1.000 | <1 | 0 | 1.000 |
Visual impairment | 4 | 2 | 0.684 | 3 | 2 | 1.000 |
Treated as randomised | % of 75 | % of 70 | % of 75 | % of 70 | ||
Auditory impairment | 33 | 17 | 0.035 | 25 | 14 | 0.145 |
Renal impairment | 9 | 11 | 0.787 | 7 | 9 | 0.759 |
Thyroid dysfunction | 13 | 7 | 0.280 | 12 | 7 | 0.404 |
Focal nodular hyperplasia of the liver | 9 | 1 | 0.064 | 9 | 1 | 0.064 |
Hepatopathy | 4 | 1 | 0.621 | 4 | 1 | 0.621 |
Peripheral neuropathy | 1 | 0 | 1.000 | 0 | 0 | n.a |
Growth retardation | 0 | 1 | 0.483 | 0 | 1 | 0.483 |
Cardiomyopathy | 0 | 3 | 0.231 | 0 | 3 | 0.231 |
Residual transverse myelopathy | 0 | 1 | 0.483 | 0 | 1 | 0.483 |
Persisting thrombocytopenia | 0 | 0 | N.A. | 0 | 0 | N.a. |
Visual impairment | 3 | 3 | 1.000 | 3 | 3 | 1.000 |
